NYSE:ARDT Ardent Health Partners Q1 2025 Earnings Report $14.82 -0.12 (-0.82%) Closing price 05/22/2025 03:59 PM EasternExtended Trading$13.70 -1.12 (-7.57%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Ardent Health Partners EPS ResultsActual EPS$0.29Consensus EPS $0.21Beat/MissBeat by +$0.08One Year Ago EPSN/AArdent Health Partners Revenue ResultsActual Revenue$1.50 billionExpected Revenue$1.50 billionBeat/MissMissed by -$355.00 thousandYoY Revenue GrowthN/AArdent Health Partners Announcement DetailsQuarterQ1 2025Date5/6/2025TimeAfter Market ClosesConference Call DateWednesday, May 7, 2025Conference Call Time10:00AM ETConference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Ardent Health Partners Q1 2025 Earnings Call TranscriptProvided by QuartrMay 7, 2025 ShareLink copied to clipboard.PresentationSkip to Participants Operator00:00:00Ladies and gentlemen, thank you for standing by, and welcome to the Ardent Health Partners First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. As a reminder, today's call is being recorded. I will now hand today's call over to David Styblo, Senior Vice President of Investor Relations. Operator00:00:34Please go ahead, David StybloSVP - Investor Relations at Ardent Health Partners00:00:35Thank you, operator, and welcome to Ardent Health's first quarter twenty twenty five earnings conference call. Joining me today is Ardent President and Chief Executive Officer, Marty Bonnick and Chief Financial Officer, Alfred Lumpstein. Marty and Alfred will provide prepared remarks, and then we will open the line to questions. Before I turn the call over to Marty, I want to remind everyone that today's discussion contains forward looking statements about future business and financial expectations. Actual results may differ significantly from those projected in today's forward looking statements due to various risks and uncertainties, including the risks described in our periodic reports filed with the Securities and Exchange Commission. David StybloSVP - Investor Relations at Ardent Health Partners00:01:13Except as required by law, we undertake no obligation to update our forward looking statements. Further, this call will include a discussion of certain non GAAP financial measures, including adjusted EBITDA and adjusted EBITDAR. Reconciliation of these measures to the closest GAAP financial measure is included in our quarterly earnings press release, which we issued yesterday evening after the market closed and is available at ardenthealth dot com. With that, I'll turn the call over to Marty. Marty BonickCEO at Ardent Health Partners00:01:40Thank you, Dave, and good morning. We appreciate everyone joining on the call and the webcast. We are pleased to report another solid quarter financial and operating performance results as we build a track record of disciplined execution in support of our strategic growth initiatives. Before diving into the details, I want to step back to focus on the big picture and underscore that Ardent is well positioned for multifaceted long term growth with an emphasis on three key areas. First, we have ample opportunities to drive strong market share growth within our existing footprint, leveraging our strong physician platform and consumer first strategy. Marty BonickCEO at Ardent Health Partners00:02:15Second, we are focused on expanding our outpatient and acute care hospital footprint and are well positioned to support this expansion with approximately $500,000,000 of cash and a favorable lease adjusted net leverage ratio of three times. Finally, we continue to drive margin expansion through operational initiatives, leveraging our scale, supply chain efficiencies and other cost saving strategies. In support of our focus on execution, I'm pleased to welcome Dave Kaspers as our Chief Operating Officer effective March 31. Dave's experience driving strategic growth at Walmart Health, Banner Health and Target Corporation's retail healthcare business will significantly complement our executive management team. Additionally, we are in the final stages of recruiting a Chief Development Officer to support our focus on M and A activities. Marty BonickCEO at Ardent Health Partners00:03:03Turning to first quarter results, we continue to deliver against our strategic objectives. Volume growth was once again solid. Admissions grew 7.6% driven by strong underlying growth and heightened flu season. Inpatient surgery growth of 3.4% was strong and benefited from our efforts to optimize transfer center operations to capture additional demand. Adjusted admissions increased 2.7%, which is on the upper end of our full year 2025 outlook of 2% to 3%. Marty BonickCEO at Ardent Health Partners00:03:33First quarter revenue increased 4% and net patient service revenue per adjusted admission grew 1.2%. Those growth rates were tempered by approximately 70 basis points due to the strategic transfer of certain oncology and infusion services to a health system partner in the middle of last year. Recall, we discussed this mechanical headwind during the third quarter twenty twenty four earnings call and we will lap that event after second quarter twenty twenty five results. These services produced roughly $10,000,000 of revenue, but were breakeven EBITDA. Additionally, I would note that our first quarter results exclude any benefit from the 2025 New Mexico DPP program that is awaiting final CMS approval. Marty BonickCEO at Ardent Health Partners00:04:13First quarter twenty twenty five adjusted EBITDA grew 2.5% to $98,000,000 In pursuit of our strategic operational excellence initiatives, we made additional progress on our supply chain during the first quarter. Supply cost as a percent of revenue declined 60 basis points year over year. We have a number of projects in the pipeline that we expect will create additional efficiencies over the next several years and continue to see an opportunity to improve margins by 100 basis to 200 basis points over the next three to four years through scale, supply chain optimization and other operating cost initiatives. Also on the cost side, the growth rate of physician professional fees was 6% in the first quarter of twenty twenty five, down from 13% growth during the same period last year. While hospital based physician subsidies remain a headwind, we are beginning to see hopeful signs that the growth rates are moderating. Marty BonickCEO at Ardent Health Partners00:05:04On the ambulatory front, we are pleased with the integration of the 18 Nex Care Urgent Care clinics that we acquired on 01/01/2025. As the year progresses, we expect this transaction to generate additional downstream volumes in our Tulsa and Albuquerque markets. Consistent with our focus on high growth midsize urban markets, we expect to continue to strategically expand ambulatory access points to meet consumer demand and drive growth. In terms of M and A, we are seeing more potential acquisition candidates as providers assess optionality in the marketplace in a more uncertain regulatory environment. We are seeing increased interest in our unique joint venture model from potential academic and non for profit partners that are in this exploratory phase. Marty BonickCEO at Ardent Health Partners00:05:47We will continue to evaluate these potential opportunities in a disciplined manner and have the balance sheet to move forward when a stockholder value enhancing opportunity presents itself. In summary, we continue to successfully execute on our strategic growth priorities during the first quarter of twenty twenty five, creating strong momentum to start the year. This puts us firmly on track to meet our full year 2025 financial guidance, which we are reaffirming today. With that, I will turn over the call to Alfred. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:06:14Thanks, Marty, and good morning to everyone on the call today. As Marty indicated, Q1 of twenty twenty five represented a very solid start to the year, and we expect to maintain our operating momentum throughout 2025. At a high level, we continue to execute across numerous key strategic initiatives during the first quarter that help set the stage for attractive long term growth. We captured incremental supply chain cost savings, improved transfer center operations, and integrated the NextCare Urgent Care acquisition. Additionally, while our earnings exposure from tariffs is minimal for 2025, we're working proactively to mitigate potential future impacts. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:06:58Like many peers, we benefit from a strong relationship with our GPO partner HealthTrust and have fixed pricing for a large majority of our supplies this year. Recognizing that the tariff outlook is fluid, we estimate the 2025 EBITDA impact is no more than a mid single digit million dollar amount based on the current tariffs in place. That said, I'll move on to first quarter results, which excluded any financial benefit from the 2025 New Mexico DPP program. While CMS has not approved the renewal yet, we're encouraged by signs of a typical program approval process between the state and CMS. First quarter revenue increased 4% to $1,500,000,000 compared to the prior year driven by adjusted admissions growth of 2.7% and net patient service revenue per adjusted admission growth of 1.2%. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:07:56Excluding the infusion and oncology transfer that Marty mentioned, growth rates for revenue and net patient service revenue per adjusted admission were 4.71.9% respectively. From a volume standpoint, demand remains durable. Admissions growth was a very strong 7.6% and adjusted admissions increased 2.7% year over year, which we believe speaks to our strong market position and growth opportunities within our current markets. Inpatient surgery growth was a solid 3.4% in the first quarter, while outpatient surgeries declined 2.3%. Overall, we estimate year over year surgical volume was impacted by approximately 1.5% from the timing of leap year. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:08:48Adjusted EBITDA increased 2.5% in the first quarter to $98,000,000 which is consistent with our expectation towards achieving full year 2025 guidance. The growth rate was impacted by a notable increase in payer claim denials when compared to the first quarter of twenty twenty four. To be clear, we aren't seeing a significant increase in denials compared to the back half of twenty twenty four, but it does create a year over year headwind. That said, we expect underlying EBITDA growth to accelerate as we lap this dynamic in the back half of the year. Marty BonickCEO at Ardent Health Partners00:09:25Turning to some specific line items, salaries and benefits expense as a percentage of revenue increased 70 basis points on a reported basis, but virtually all of Marty BonickCEO at Ardent Health Partners00:09:35that increase was driven by post IPO stock compensation. We're pleased with our operational improvement around contract labor, which declined 60 basis points year over year to 3.8 as a percentage of total salaries and benefits. We continue to see strong nursing retention rates and a stable contract labor rate environment. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:09:59Marty already covered our improving trends in professional fees and supplies, so I won't rehash those. Moving on to cash flow and liquidity, we ended the first quarter with total cash of $495,000,000 and total debt outstanding of $1,100,000,000 Our total available liquidity at the end of the first quarter was $790,000,000 Cash used in operating activities during the first quarter was $25,000,000 compared to $15,000,000 used in the first quarter of twenty twenty four. As a reminder, Q1 is traditionally our weakest cash flow quarter largely due to payment timing related to year end accruals. Capital expenditures during the first quarter were $23,000,000 and we expect that to ramp throughout the year. Our total net leverage as calculated under our credit agreements was 1.4 times and our lease adjusted net leverage was three times. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:11:02On a related note, I'm pleased to share that late last month S and P upgraded our credit rating to B plus from B reflecting our improved net leverage and cash flow profile. This action affirms the results of our fiscal and operating strategies and will help strengthen any future financing opportunities. Overall, we remain firmly on track to achieve our 2025 financial outlook, which we are reaffirming today. With that, I'd like to turn the call back to Marty for a few final comments on the quarter before we open the call Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:11:36to questions. Marty? Marty BonickCEO at Ardent Health Partners00:11:38Thank you, Alfred. In summary, we continue to make substantial progress as we execute on our strategic growth initiatives and leverage the consumer focused platform we have built to create long term stockholder value. We are pleased with our solid start to 2025 underscored by strong demand trends. Marty BonickCEO at Ardent Health Partners00:11:54We continue to sharpen our focus on market share growth, taking a disciplined approach to evaluating opportunities in both the ambulatory space as well as acute care hospitals. With leverage of three times and ample cash, we will continue to assess opportunities to execute on this strategy. Finally, we remain focused on operational excellence initiatives to drive margin expansion over the next several years. I want to close by thanking our 25,000 team members and more than 1,800 employed and affiliated providers who continue to deliver exceptional care to patients across the communities we serve. Together, we are focused on making health care better and advancing our purpose of caring for our patients, our communities, and one another. Marty BonickCEO at Ardent Health Partners00:12:32With that, operator, please open the line for questions. Operator00:12:57Your first question is from the line of Ann Hynes with Mizuho. Anna, your line is open. There's no response from that line. We'll go to the next question. Your next question is from Whit Mayo with Leerink Partners. Whit MayoSenior Managing Director at Leerink Partners00:13:25Hey, thanks. I'm still trying to get a feel for the seasonality of this business. And when I exclude the supplemental payments from the fourth quarter of last year, it looks like EBITDA may have declined call it 20% or so. Is that a normal sequential decline? And you referenced stronger flu and the volumes look really good. Whit MayoSenior Managing Director at Leerink Partners00:13:45So I would have expected to see better than normal sequential growth. So I'm trying to put this sort of in perspective with normal seasonal patterns to the way your earnings develop. Thanks. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:13:56Sure. Thanks for the question, Whit. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:13:57This is Alfred. Yes, I Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:13:58would say it's not abnormal. There's obviously any number of puts and takes. From our perspective, the strength of the flu season is not a particular tailwind to the business. It certainly drives higher volumes, but also comes with some lower acuity and some incumbent higher cost premium pay as we care for those patients. So, yes, I would not put that into the tailwind or into the tailwind category. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:14:26Clearly, we mentioned payer denials, but again, on a sequential basis, we didn't really see that as a sequential it was more of a year over year impact than a sequential impact. So, again, with some amount of normal puts and takes, I think you can put that into, you know, the the bounce of a normal type of seasonality with the strength of year end and then the reset of deductibles and co pays, at the start of the year and then other kind of timing things like, reset of payroll taxes, etcetera. You have a little bit of a cost burden in q one that happens as well, and and our races go into effect in Q1. So again, there's just a little bit of a sequential dynamic there. But, yes, I would not call out anything outside of the balance of normal. Whit MayoSenior Managing Director at Leerink Partners00:15:14Okay. And maybe just to follow-up on the elevated denials, I presume that that's MA. And what I'm hearing, I guess, is this is a continuation of what you saw from last year? Or are there new changes in payer behavior or dispute resolution, any changes with length of stay on MA? Just any additional color might be helpful. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:15:37I Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:15:38think what you're hearing is very consistent with what we're experiencing. Yes, a continuation of last year. We really saw that step up happen in, you know, in the middle of the year. You know, a couple of things we would call out there. You know, I would say there has been a continuation of a slowdown in payments even on clean claims. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:16:00That's maybe, again, while denials have not accelerated, there's maybe been a bit of an acceleration from just, length of time to pay a clean claim, and that's certainly showing up, impacting our cash flow numbers. But, no, we're not, you're you're, again, how you frame the question with is consistent with what we're saying. Operator00:16:21Your Operator00:16:23next question is from the line of Anne Hines from Mizuho. Ann HynesSenior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial Group00:16:28Hi. Sorry about that. I had some technical difficulties. Maybe just on the supply chain initiatives. Can you tell us like why you actually have so much opportunity versus your peers? Ann HynesSenior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial Group00:16:39Are you involved in a GPO? And maybe if you really can dig into, like, the type of opportunities you have that will create that type of margin expansion, that would be very helpful. Marty BonickCEO at Ardent Health Partners00:16:49Yeah. Anne, this is Marty. Thanks for the question. We do participate, with HealthTrust as our GPO partner and very similar to our peer group, and so that helps us with our day to day contracting. But the utilization within our service lines is where we still see opportunity for improvement. Marty BonickCEO at Ardent Health Partners00:17:08This is an ongoing journey that we have and have continued to see improvement as we've gone through both certification as well as looking at physician preference items, and most notably, the action we took last summer by partnering with one of our academic institutions to move some of our oncology infusion services. The drug costs for those services have varying reimbursements based upon the geographies and markets that we're in, and so we continue to see opportunities to further address those drug costs in concert with our partners, as well as just general physician preference items that we're continuing to negotiate across key service lines as we're seeing volumes improve. Ann HynesSenior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial Group00:17:53Great. And then it sounds like the underlying admission growth was better than your expectations. Besides flu, are there any other areas that you would call out? Thanks. Marty BonickCEO at Ardent Health Partners00:18:03Yeah. This is Marty again. Marty BonickCEO at Ardent Health Partners00:18:06had Marty BonickCEO at Ardent Health Partners00:18:07a big focus around our transfer centers and making sure, both from an internal efficiency, that we've got good bed turnover through, like, stay initiatives and optimizing the transfer centers that we have regionalized across the company. And so I think you are seeing the strong impact of the flu is the principal reason that we have coming through there. But, you know, as we've gone through service line rationalizations, that helped lead to an increase in our inpatient surgeries and, again, the focus on the transfer centers of bringing in cases from across our regions into our tertiary centers. Those the combination of those activities is what's driving that growth. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:18:43And this is Alfred. And I would just add that, you know, again, we believe it's also representative of the strength of the markets we're in and the underlying growth of those markets. Operator00:18:54Your next question is from the line of Craig Hettenbach with Morgan Stanley. Craig HettenbachExecutive Director at Morgan Stanley00:19:00Thank you. Marty, can you just build on the commentary of just durability of demand? Any areas of care where you're seeing that most pronounced? And anything to note in terms of how broad based this is versus market specific? Marty BonickCEO at Ardent Health Partners00:19:15Yes. Craig, this is Marty. So just as building on what Alfred said, we've referenced before the strength of our market's growing on average, you know, about 3% a year, and so we see that as very durable. We know that there's some commentary between the payers and the providers, in terms of whether there's pent up demand. We don't subscribe to that theory. Marty BonickCEO at Ardent Health Partners00:19:35The strength of our markets, coupled with the strength of our performance, gives us strong conviction that we will continue to see strong volume growth. We accentuate that by the operational improvements we're making to be able to service that growth. But the strength of the markets that we're in gives us good conviction that these volumes are durable to from positive growth rate perspective. Craig HettenbachExecutive Director at Morgan Stanley00:20:00Got it. And then just as a follow-up on the COO hire, just any areas of strategic focus for him and and then also kind of experience he brings to your organization as you continue to look to scale the business? Marty BonickCEO at Ardent Health Partners00:20:12Yeah. Dave Dave's about one month on the job with us and is doing a great job, really just helping to, again, complement the existing executive team that we've put together. We've got great subject matter expertise across our hospitals, our health services, and our corporate services. Dave's background with both the consumer and retail focus will accentuate our consumer growth strategies as we go through the markets. And just to focus on and continued focus on integration and optimization of the entire platform, we've talked about the centralized centralized services that we've created in the years leading up to the IPO last summer. Marty BonickCEO at Ardent Health Partners00:20:49But we also said that we know that we've got 100 to 200 basis points of margin expansion to achieve over the next several years, and Dave will be a key focus in driving that performance improvement, coupled with the expected growth that we will see in new market or new hospital growth, complementing our existing markets. That integration activity will be paramount to making sure we can extract value from any transactions and making those accretive for the company. And so he'll have purview over, the execution of our ongoing initiatives as well as, that integration of new activity and growth into the system. Operator00:21:28Your next question is from the line of Ben Hendrix with RBC Capital Markets. Ben HendrixVice President at RBC Capital Markets00:21:35Great. Thank you very much. Just wanted to get an update on the expansion initiatives or the strategic initiatives you called out, specifically expanding your outpatient and acute footprint. Just any update on how conversations are going with potential new market opportunities and sellers in those markets? How are they thinking about valuation in the amid the uncertainty on the Medicaid policy changes and kind of just what you're seeing in terms of seller appetite? Ben HendrixVice President at RBC Capital Markets00:22:08Thanks. Marty BonickCEO at Ardent Health Partners00:22:09Ben, this is Marty again. Thanks for the question. We continue to focus on a multipart growth strategy. The first, we always said, was going to be inside of our markets. While we've got very strong inpatient market share, we know that there's still a lot of outpatient development work to be captured. Marty BonickCEO at Ardent Health Partners00:22:26Again, the acquisition we did with the NextCare Urgent Care assets in our Albuquerque and Tulsa markets, the 18 urgent care centers we bought, is a great indicator of that continued focus that we're going to have of strengthening the access points in our markets, strengthening our positions in those markets, and building out a more robust footprint, first and foremost. On the second part, in terms of new markets or new hospital growth, I would say the pipeline continues to build. Since going public, our visibility, you know, has, taken a new stage, and we've got more inbound calls, coming from, academic partners in particular, that have taken note of the model that we have and have a desire to grow inside of their respective regions but may not have, the balance sheet or the integrating operating experience, to expand into new regions and see Ardent as a a good target partner. So I'll say the conversations in the pipeline are growing, which is the reason that we're focusing on bringing in a dedicated chief development officer into the company, to be able to capitalize on those opportunities. In terms of valuations, you know, you've certainly seen some headline valuations that are above, historic norms and averages. Marty BonickCEO at Ardent Health Partners00:23:36I would characterize those as largely sort of one off strategic acquisitions for certain existing systems in a given geography. We believe that the overall valuations will continue to trade somewhere in the normal sense of where this industry has historically been. And any acquisition that we focus on is going to have to be something that we see as accretive to the company in the near term, call it, the first twenty four months, where we can see absent purchase price synergies that will help us to delever a transaction and make it accretive for shareholders. Ben HendrixVice President at RBC Capital Markets00:24:12Great. Thanks for the color. Operator00:24:17Your next question is from the line of Joanna Gajuk with Bank of America. Joanna GajukEquity Research Analyst at Bank of America00:24:24Hi, good morning. Thanks so much for taking the question. So I guess a follow-up on that comment around, I guess, to the prior question. So you mentioned that there's interest to it sounds like, receiving from the nonprofits and academic centers to partner. So can you give us a sense of those preliminary preliminary, you know, are these, you know, systems waiting essentially to see what's gonna happen or they're kinda ready to kinda, you know, do something right now? Joanna GajukEquity Research Analyst at Bank of America00:24:56So, essentially, what I was asking is sort of what, you know, a close of getting something done. Should we expect something this year or just this more kinda like next year when the dust sells? Any kind of indication, I guess, would be helpful. Marty BonickCEO at Ardent Health Partners00:25:09Yes. Marty BonickCEO at Ardent Health Partners00:25:10Joanne, this is Marty. I'll offer to chime in if there's additional. But we've been pretty open that we went public with the expectation of growth. We believe we've got a strong operating model that would be valuable to enter into new markets where we could create a partnership and, you know, create something more valuable for that target seller than that they were able to achieve on their own. We don't have anything definitive to announce today, obviously, and we will appropriately message that when there is. Marty BonickCEO at Ardent Health Partners00:25:39But I would say that there's a mix of conversations going on with potential near term opportunities as well as exploratory conversations about what future growth can look like in a in a given geography. You know, we are focusing on a mix of hospital acquisitions that would be both complementary to our existing markets or or state footprints we're in as well as new. And so, you know, we're just encouraged by that the the pipeline of growth and, again, the the reason why we're bringing on dedicated chief development officer to help nurture those relationships, conversations, and bring those to fruition. But we've been saying we've been hopeful that we will see some type of a transaction, whether that's a tuck in or a new market, know, still in this calendar year. Joanna GajukEquity Research Analyst at Bank of America00:26:25Okay. If I may, on the New Mexico DPP, like you said, you know, no approval yet, but there's some approvals coming out. So so any indication, like, would you assume to get this finalized by the end of q two? I mean, we're already in May. Thank you. Marty BonickCEO at Ardent Health Partners00:26:42Yeah. This is Marty again. On the DPP programs, we are starting to see a number of analysts noting that renewals of other states happening. We remain convicted that these programs are durable, You know, from our conversations at Washington, D. C. Marty BonickCEO at Ardent Health Partners00:26:58With elected officials, they know the importance of these programs to the states. Again, these DPPs were started under the first Trump administration, and I think the sense that we're seeing these new other state approvals come through are consistent with our conversations that we're having with the elected officials, both in the state and CMS, that it's just a matter of processing through these. And, you know, we are expecting approval. The the timing, we are hopeful for to see a q two approval, but, obviously, we can't control that. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:27:28And this is Alfred, Joanne. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:27:29The only thing I would add is that, you Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:27:31know, we stay close to our contacts in New Mexico, and I think we've been clear that all of the indications are that, you know, things are progressing as you would expect, and a very normal tracking towards an approval. Operator00:27:46Your next question is from the line of Matthew Gillmor with KeyBanc. Matthew GillmorDirector & Equity Research Analyst at KeyBanc Capital Markets00:27:53Hey, thanks. Wanted to ask about exchange volumes and payer mix. I think the presentation made reference to strength with exchange volumes. Can you provide some details in terms of the magnitude of the growth in the quarter and maybe update us in terms of the percent of revenue that's tied to exchanges versus, I think, the 3.6% you talked about for 'twenty four? Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:28:15Sure, Matt. This is Alfred. You know, like, all of our peers, we are seeing very strong exchange growth. For example, admissions in the quarter grew 40, in q one. That's a combination of, improvement in our additional enrollment in exchanges as well as new plans that we have that are ramping. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:28:38So our exchange volume growth, was significant. And, you know, today, q one, we're operating in the mid single digits as a percent of revenue. Matthew GillmorDirector & Equity Research Analyst at KeyBanc Capital Markets00:28:48Got it. That's helpful. And then following up on the comment around the moderation in professional expenses, I was hoping you could sort of unpack that a little in terms of the hospital based physician expense. You know, where are you seeing improvement? And, you know, are are you confident and comfortable that that'll be sort of a durable moderation? Matthew GillmorDirector & Equity Research Analyst at KeyBanc Capital Markets00:29:09Any any additional details there would be great. Thanks. Marty BonickCEO at Ardent Health Partners00:29:12Yeah, Matt. This is Marty. You know, we we have expected to see as we, you know, we could get guidance earlier in the year that, this was still gonna be an inflation that was north of, you know, sort of general inflation, and, you know, we've modeled that as such, and we are seeing that continue. And we are encouraged that it is moderating from the peak in 'twenty three. The rates came down a bit in 'twenty four. Marty BonickCEO at Ardent Health Partners00:29:35The growth, I should say, came down a bit in 'twenty four. We expect that to continue to moderate 'twenty five, but still be above normal inflation levels. So while Q1 was slightly ahead of where we thought things might be, we know, which is given some of the uncertainty of certain specialties, radiology is one that has been a bigger growth area as well as continued pressures in anesthesiology that we expect to see some continuation of this trend going throughout the remainder of the year as we had forecasted and guided earlier in the year. Operator00:30:16Your next question is from the line of Benjamin Rossi with JPMorgan. Benjamin RossiEquity Research Associate at JP Morgan00:30:24Great. Thanks for the question. So with 1Q revenue per adjusted admission at about 1.2% on respiratory tract acuity and more challenging year over year comp. Benjamin RossiEquity Research Associate at JP Morgan00:30:36To start there, is there anything else Benjamin RossiEquity Research Associate at JP Morgan00:30:38from a payer mix or acuity perspective that we aren't seeing within there such as additional drag from your efforts or rationalizing your outpatient surgery offerings? And then in reaffirming your guide, what puts and takes are you factoring into reaching the lower end or upper end of your 2025 pricing guidance of 2.1% to 4.4% year over year? Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:30:59Ben, it's Alfred. I'll start with the first part of your question on the NPR per AA growth of 1.2%. You touched on a piece of it, the service mix and acuity. Clearly, that was on a year over year basis a drag. We continue to see good the year over year commercial rate increases have been very consistent with our expectations. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:31:24The other items that were dragged on a year over year basis, we talked about the denials, you know, which we will lap in the middle of the year. So you'll get a more normalized, you know, growth rate on a year over year basis. And then the last thing is is that transfer, and Marty touched on it in his comments, the transfer of the oncology services. You know, that was about 70 basis points, as well. So, really, those three items, were the were the drag on a year over year basis. Benjamin RossiEquity Research Associate at JP Morgan00:31:55Great. And then as a follow-up on the transfer center operations, you mentioned the improvements to your transfer center more broadly on a regional basis. Could you just walk us through those efforts and your approach more broadly to inpatient capacity and related patient throughput during this elevated patient utilization backdrop? Marty BonickCEO at Ardent Health Partners00:32:15Yes, Evan, this is Marty. So we have regionalized our transfer center operations. And, as you all know, we have one instance of EPIC as our electronic health record and really our clinical operating system that helps us drive and have visibility in terms of where we have capacity opportunities. Know, taking that technology and the organization of those services has allowed us to have a very, you know, seamless process for outlying rural regional hospitals to be able to transfer patients into our networks and help us to drive that volume to the most appropriate setting. So not only are we trying to maximize volumes coming into our tertiary hospitals, but our secondary hospitals, which may not have gotten the original call, we're able to relocate those patients, where we've got the appropriate clinical mix of physicians and services to to service those patients and manage capacity and demand across the a broader network. Marty BonickCEO at Ardent Health Partners00:33:07And so before that that was all happening, you know, on a one off basis, and if you called hospital x and they had availability, they'd accept it. Now you're calling the market, and the market is helping to distribute those patients more effectively across our footprint, which is helping us to see increased pull through in those transfers, getting placed in in one of our hospital beds. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:33:28And, Ben, this is Alfred. I wanna go back to the first part of your question because you asked about the, you know, kinda what are the range of outcome in terms of the items would it that would affect the range from the top end to the bottom end of our guidance. You know, obviously, we're very pleased with the start of the year and the solid Q1 that we had. I would just point you back to the things we've talked about, the pressure of professional fees, the payer behaviors and denials is their variance to those expectations. And then, of course, tariffs, we've touched on relatively minor in terms of the overall exposure, but certainly not something that we had anticipated in our guide. Operator00:34:09At this time, there are no further questions. I will now hand the call back over to management for closing remarks. Marty BonickCEO at Ardent Health Partners00:34:16Thank you, everybody, for your time and attention. We appreciate the support of Ardent and our performance. If there's any follow-up questions, please refer those to Dave Styblo, Head of Investor Relations for Ardent. Thank you, everybody. Operator00:34:29This concludes today's call. Thank you for joining. You may now disconnect your lines.Read moreParticipantsExecutivesDavid StybloSVP - Investor RelationsMarty BonickCEOAlfred LumsdaineChief Financial OfficerAnalystsWhit MayoSenior Managing Director at Leerink PartnersAnn HynesSenior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial GroupCraig HettenbachExecutive Director at Morgan StanleyBen HendrixVice President at RBC Capital MarketsJoanna GajukEquity Research Analyst at Bank of AmericaMatthew GillmorDirector & Equity Research Analyst at KeyBanc Capital MarketsBenjamin RossiEquity Research Associate at JP MorganPowered by Key Takeaways Ardent delivered a solid Q1 with admissions up 7.6% and adjusted admissions up 2.7% (upper end of 2025 guidance), driving 4% revenue growth despite a 70 bp drag from last year’s oncology/infusion transfer. Adjusted EBITDA rose 2.5% to $98 million, aided by a 60 bp reduction in supply costs and a moderation in physician professional fee inflation to 6%, as the company targets an additional 100–200 bp of margin expansion over the next 3–4 years. With approximately $500 million of cash, a 3x lease-adjusted leverage, and reaffirmed full-year guidance, Ardent remains focused on three strategic priorities: expanding market share in existing markets, growing outpatient and acute care footprints, and driving operational margin improvements. Ardent bolstered its leadership team with the appointment of Dave Kaspers as COO and is finalizing a Chief Development Officer hire to accelerate execution and integrations across its growth initiatives. The company continues to expand ambulatory access, highlighted by the integration of 18 NexCare urgent care clinics, and sees a growing pipeline of M&A opportunities with non-profit and academic partners, leveraging its joint-venture model to pursue disciplined acquisitions. AI Generated. May Contain Errors.Conference Call Audio Live Call not available Earnings Conference CallArdent Health Partners Q1 202500:00 / 00:00Speed:1x1.25x1.5x2xTranscript SectionsPresentationParticipants Earnings DocumentsSlide DeckPress Release(8-K)Quarterly report(10-Q) Ardent Health Partners Earnings HeadlinesStephens Reiterates "Overweight" Rating for Ardent Health Partners (NYSE:ARDT)May 23 at 2:29 AM | americanbankingnews.comArdent Health Appoints Chief Development Officer to Lead Strategic GrowthMay 19, 2025 | gurufocus.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 23, 2025 | Brownstone Research (Ad)Analysts Set Ardent Health Partners, LLC (NYSE:ARDT) Price Target at $20.75May 19, 2025 | americanbankingnews.comArdent Health Partners' (ARDT) Outperform Rating Reiterated at Royal Bank of CanadaMay 17, 2025 | americanbankingnews.comLeerink Partnrs Brokers Lower Earnings Estimates for ARDTMay 13, 2025 | americanbankingnews.comSee More Ardent Health Partners Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ardent Health Partners? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ardent Health Partners and other key companies, straight to your email. Email Address About Ardent Health PartnersArdent Health Partners (NYSE:ARDT), Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.View Ardent Health Partners ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds Upcoming Earnings PDD (5/27/2025)AutoZone (5/27/2025)Bank of Nova Scotia (5/27/2025)NVIDIA (5/28/2025)Synopsys (5/28/2025)Bank of Montreal (5/28/2025)Salesforce (5/28/2025)Costco Wholesale (5/29/2025)Marvell Technology (5/29/2025)Canadian Imperial Bank of Commerce (5/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PresentationSkip to Participants Operator00:00:00Ladies and gentlemen, thank you for standing by, and welcome to the Ardent Health Partners First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. As a reminder, today's call is being recorded. I will now hand today's call over to David Styblo, Senior Vice President of Investor Relations. Operator00:00:34Please go ahead, David StybloSVP - Investor Relations at Ardent Health Partners00:00:35Thank you, operator, and welcome to Ardent Health's first quarter twenty twenty five earnings conference call. Joining me today is Ardent President and Chief Executive Officer, Marty Bonnick and Chief Financial Officer, Alfred Lumpstein. Marty and Alfred will provide prepared remarks, and then we will open the line to questions. Before I turn the call over to Marty, I want to remind everyone that today's discussion contains forward looking statements about future business and financial expectations. Actual results may differ significantly from those projected in today's forward looking statements due to various risks and uncertainties, including the risks described in our periodic reports filed with the Securities and Exchange Commission. David StybloSVP - Investor Relations at Ardent Health Partners00:01:13Except as required by law, we undertake no obligation to update our forward looking statements. Further, this call will include a discussion of certain non GAAP financial measures, including adjusted EBITDA and adjusted EBITDAR. Reconciliation of these measures to the closest GAAP financial measure is included in our quarterly earnings press release, which we issued yesterday evening after the market closed and is available at ardenthealth dot com. With that, I'll turn the call over to Marty. Marty BonickCEO at Ardent Health Partners00:01:40Thank you, Dave, and good morning. We appreciate everyone joining on the call and the webcast. We are pleased to report another solid quarter financial and operating performance results as we build a track record of disciplined execution in support of our strategic growth initiatives. Before diving into the details, I want to step back to focus on the big picture and underscore that Ardent is well positioned for multifaceted long term growth with an emphasis on three key areas. First, we have ample opportunities to drive strong market share growth within our existing footprint, leveraging our strong physician platform and consumer first strategy. Marty BonickCEO at Ardent Health Partners00:02:15Second, we are focused on expanding our outpatient and acute care hospital footprint and are well positioned to support this expansion with approximately $500,000,000 of cash and a favorable lease adjusted net leverage ratio of three times. Finally, we continue to drive margin expansion through operational initiatives, leveraging our scale, supply chain efficiencies and other cost saving strategies. In support of our focus on execution, I'm pleased to welcome Dave Kaspers as our Chief Operating Officer effective March 31. Dave's experience driving strategic growth at Walmart Health, Banner Health and Target Corporation's retail healthcare business will significantly complement our executive management team. Additionally, we are in the final stages of recruiting a Chief Development Officer to support our focus on M and A activities. Marty BonickCEO at Ardent Health Partners00:03:03Turning to first quarter results, we continue to deliver against our strategic objectives. Volume growth was once again solid. Admissions grew 7.6% driven by strong underlying growth and heightened flu season. Inpatient surgery growth of 3.4% was strong and benefited from our efforts to optimize transfer center operations to capture additional demand. Adjusted admissions increased 2.7%, which is on the upper end of our full year 2025 outlook of 2% to 3%. Marty BonickCEO at Ardent Health Partners00:03:33First quarter revenue increased 4% and net patient service revenue per adjusted admission grew 1.2%. Those growth rates were tempered by approximately 70 basis points due to the strategic transfer of certain oncology and infusion services to a health system partner in the middle of last year. Recall, we discussed this mechanical headwind during the third quarter twenty twenty four earnings call and we will lap that event after second quarter twenty twenty five results. These services produced roughly $10,000,000 of revenue, but were breakeven EBITDA. Additionally, I would note that our first quarter results exclude any benefit from the 2025 New Mexico DPP program that is awaiting final CMS approval. Marty BonickCEO at Ardent Health Partners00:04:13First quarter twenty twenty five adjusted EBITDA grew 2.5% to $98,000,000 In pursuit of our strategic operational excellence initiatives, we made additional progress on our supply chain during the first quarter. Supply cost as a percent of revenue declined 60 basis points year over year. We have a number of projects in the pipeline that we expect will create additional efficiencies over the next several years and continue to see an opportunity to improve margins by 100 basis to 200 basis points over the next three to four years through scale, supply chain optimization and other operating cost initiatives. Also on the cost side, the growth rate of physician professional fees was 6% in the first quarter of twenty twenty five, down from 13% growth during the same period last year. While hospital based physician subsidies remain a headwind, we are beginning to see hopeful signs that the growth rates are moderating. Marty BonickCEO at Ardent Health Partners00:05:04On the ambulatory front, we are pleased with the integration of the 18 Nex Care Urgent Care clinics that we acquired on 01/01/2025. As the year progresses, we expect this transaction to generate additional downstream volumes in our Tulsa and Albuquerque markets. Consistent with our focus on high growth midsize urban markets, we expect to continue to strategically expand ambulatory access points to meet consumer demand and drive growth. In terms of M and A, we are seeing more potential acquisition candidates as providers assess optionality in the marketplace in a more uncertain regulatory environment. We are seeing increased interest in our unique joint venture model from potential academic and non for profit partners that are in this exploratory phase. Marty BonickCEO at Ardent Health Partners00:05:47We will continue to evaluate these potential opportunities in a disciplined manner and have the balance sheet to move forward when a stockholder value enhancing opportunity presents itself. In summary, we continue to successfully execute on our strategic growth priorities during the first quarter of twenty twenty five, creating strong momentum to start the year. This puts us firmly on track to meet our full year 2025 financial guidance, which we are reaffirming today. With that, I will turn over the call to Alfred. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:06:14Thanks, Marty, and good morning to everyone on the call today. As Marty indicated, Q1 of twenty twenty five represented a very solid start to the year, and we expect to maintain our operating momentum throughout 2025. At a high level, we continue to execute across numerous key strategic initiatives during the first quarter that help set the stage for attractive long term growth. We captured incremental supply chain cost savings, improved transfer center operations, and integrated the NextCare Urgent Care acquisition. Additionally, while our earnings exposure from tariffs is minimal for 2025, we're working proactively to mitigate potential future impacts. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:06:58Like many peers, we benefit from a strong relationship with our GPO partner HealthTrust and have fixed pricing for a large majority of our supplies this year. Recognizing that the tariff outlook is fluid, we estimate the 2025 EBITDA impact is no more than a mid single digit million dollar amount based on the current tariffs in place. That said, I'll move on to first quarter results, which excluded any financial benefit from the 2025 New Mexico DPP program. While CMS has not approved the renewal yet, we're encouraged by signs of a typical program approval process between the state and CMS. First quarter revenue increased 4% to $1,500,000,000 compared to the prior year driven by adjusted admissions growth of 2.7% and net patient service revenue per adjusted admission growth of 1.2%. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:07:56Excluding the infusion and oncology transfer that Marty mentioned, growth rates for revenue and net patient service revenue per adjusted admission were 4.71.9% respectively. From a volume standpoint, demand remains durable. Admissions growth was a very strong 7.6% and adjusted admissions increased 2.7% year over year, which we believe speaks to our strong market position and growth opportunities within our current markets. Inpatient surgery growth was a solid 3.4% in the first quarter, while outpatient surgeries declined 2.3%. Overall, we estimate year over year surgical volume was impacted by approximately 1.5% from the timing of leap year. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:08:48Adjusted EBITDA increased 2.5% in the first quarter to $98,000,000 which is consistent with our expectation towards achieving full year 2025 guidance. The growth rate was impacted by a notable increase in payer claim denials when compared to the first quarter of twenty twenty four. To be clear, we aren't seeing a significant increase in denials compared to the back half of twenty twenty four, but it does create a year over year headwind. That said, we expect underlying EBITDA growth to accelerate as we lap this dynamic in the back half of the year. Marty BonickCEO at Ardent Health Partners00:09:25Turning to some specific line items, salaries and benefits expense as a percentage of revenue increased 70 basis points on a reported basis, but virtually all of Marty BonickCEO at Ardent Health Partners00:09:35that increase was driven by post IPO stock compensation. We're pleased with our operational improvement around contract labor, which declined 60 basis points year over year to 3.8 as a percentage of total salaries and benefits. We continue to see strong nursing retention rates and a stable contract labor rate environment. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:09:59Marty already covered our improving trends in professional fees and supplies, so I won't rehash those. Moving on to cash flow and liquidity, we ended the first quarter with total cash of $495,000,000 and total debt outstanding of $1,100,000,000 Our total available liquidity at the end of the first quarter was $790,000,000 Cash used in operating activities during the first quarter was $25,000,000 compared to $15,000,000 used in the first quarter of twenty twenty four. As a reminder, Q1 is traditionally our weakest cash flow quarter largely due to payment timing related to year end accruals. Capital expenditures during the first quarter were $23,000,000 and we expect that to ramp throughout the year. Our total net leverage as calculated under our credit agreements was 1.4 times and our lease adjusted net leverage was three times. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:11:02On a related note, I'm pleased to share that late last month S and P upgraded our credit rating to B plus from B reflecting our improved net leverage and cash flow profile. This action affirms the results of our fiscal and operating strategies and will help strengthen any future financing opportunities. Overall, we remain firmly on track to achieve our 2025 financial outlook, which we are reaffirming today. With that, I'd like to turn the call back to Marty for a few final comments on the quarter before we open the call Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:11:36to questions. Marty? Marty BonickCEO at Ardent Health Partners00:11:38Thank you, Alfred. In summary, we continue to make substantial progress as we execute on our strategic growth initiatives and leverage the consumer focused platform we have built to create long term stockholder value. We are pleased with our solid start to 2025 underscored by strong demand trends. Marty BonickCEO at Ardent Health Partners00:11:54We continue to sharpen our focus on market share growth, taking a disciplined approach to evaluating opportunities in both the ambulatory space as well as acute care hospitals. With leverage of three times and ample cash, we will continue to assess opportunities to execute on this strategy. Finally, we remain focused on operational excellence initiatives to drive margin expansion over the next several years. I want to close by thanking our 25,000 team members and more than 1,800 employed and affiliated providers who continue to deliver exceptional care to patients across the communities we serve. Together, we are focused on making health care better and advancing our purpose of caring for our patients, our communities, and one another. Marty BonickCEO at Ardent Health Partners00:12:32With that, operator, please open the line for questions. Operator00:12:57Your first question is from the line of Ann Hynes with Mizuho. Anna, your line is open. There's no response from that line. We'll go to the next question. Your next question is from Whit Mayo with Leerink Partners. Whit MayoSenior Managing Director at Leerink Partners00:13:25Hey, thanks. I'm still trying to get a feel for the seasonality of this business. And when I exclude the supplemental payments from the fourth quarter of last year, it looks like EBITDA may have declined call it 20% or so. Is that a normal sequential decline? And you referenced stronger flu and the volumes look really good. Whit MayoSenior Managing Director at Leerink Partners00:13:45So I would have expected to see better than normal sequential growth. So I'm trying to put this sort of in perspective with normal seasonal patterns to the way your earnings develop. Thanks. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:13:56Sure. Thanks for the question, Whit. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:13:57This is Alfred. Yes, I Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:13:58would say it's not abnormal. There's obviously any number of puts and takes. From our perspective, the strength of the flu season is not a particular tailwind to the business. It certainly drives higher volumes, but also comes with some lower acuity and some incumbent higher cost premium pay as we care for those patients. So, yes, I would not put that into the tailwind or into the tailwind category. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:14:26Clearly, we mentioned payer denials, but again, on a sequential basis, we didn't really see that as a sequential it was more of a year over year impact than a sequential impact. So, again, with some amount of normal puts and takes, I think you can put that into, you know, the the bounce of a normal type of seasonality with the strength of year end and then the reset of deductibles and co pays, at the start of the year and then other kind of timing things like, reset of payroll taxes, etcetera. You have a little bit of a cost burden in q one that happens as well, and and our races go into effect in Q1. So again, there's just a little bit of a sequential dynamic there. But, yes, I would not call out anything outside of the balance of normal. Whit MayoSenior Managing Director at Leerink Partners00:15:14Okay. And maybe just to follow-up on the elevated denials, I presume that that's MA. And what I'm hearing, I guess, is this is a continuation of what you saw from last year? Or are there new changes in payer behavior or dispute resolution, any changes with length of stay on MA? Just any additional color might be helpful. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:15:37I Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:15:38think what you're hearing is very consistent with what we're experiencing. Yes, a continuation of last year. We really saw that step up happen in, you know, in the middle of the year. You know, a couple of things we would call out there. You know, I would say there has been a continuation of a slowdown in payments even on clean claims. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:16:00That's maybe, again, while denials have not accelerated, there's maybe been a bit of an acceleration from just, length of time to pay a clean claim, and that's certainly showing up, impacting our cash flow numbers. But, no, we're not, you're you're, again, how you frame the question with is consistent with what we're saying. Operator00:16:21Your Operator00:16:23next question is from the line of Anne Hines from Mizuho. Ann HynesSenior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial Group00:16:28Hi. Sorry about that. I had some technical difficulties. Maybe just on the supply chain initiatives. Can you tell us like why you actually have so much opportunity versus your peers? Ann HynesSenior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial Group00:16:39Are you involved in a GPO? And maybe if you really can dig into, like, the type of opportunities you have that will create that type of margin expansion, that would be very helpful. Marty BonickCEO at Ardent Health Partners00:16:49Yeah. Anne, this is Marty. Thanks for the question. We do participate, with HealthTrust as our GPO partner and very similar to our peer group, and so that helps us with our day to day contracting. But the utilization within our service lines is where we still see opportunity for improvement. Marty BonickCEO at Ardent Health Partners00:17:08This is an ongoing journey that we have and have continued to see improvement as we've gone through both certification as well as looking at physician preference items, and most notably, the action we took last summer by partnering with one of our academic institutions to move some of our oncology infusion services. The drug costs for those services have varying reimbursements based upon the geographies and markets that we're in, and so we continue to see opportunities to further address those drug costs in concert with our partners, as well as just general physician preference items that we're continuing to negotiate across key service lines as we're seeing volumes improve. Ann HynesSenior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial Group00:17:53Great. And then it sounds like the underlying admission growth was better than your expectations. Besides flu, are there any other areas that you would call out? Thanks. Marty BonickCEO at Ardent Health Partners00:18:03Yeah. This is Marty again. Marty BonickCEO at Ardent Health Partners00:18:06had Marty BonickCEO at Ardent Health Partners00:18:07a big focus around our transfer centers and making sure, both from an internal efficiency, that we've got good bed turnover through, like, stay initiatives and optimizing the transfer centers that we have regionalized across the company. And so I think you are seeing the strong impact of the flu is the principal reason that we have coming through there. But, you know, as we've gone through service line rationalizations, that helped lead to an increase in our inpatient surgeries and, again, the focus on the transfer centers of bringing in cases from across our regions into our tertiary centers. Those the combination of those activities is what's driving that growth. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:18:43And this is Alfred. And I would just add that, you know, again, we believe it's also representative of the strength of the markets we're in and the underlying growth of those markets. Operator00:18:54Your next question is from the line of Craig Hettenbach with Morgan Stanley. Craig HettenbachExecutive Director at Morgan Stanley00:19:00Thank you. Marty, can you just build on the commentary of just durability of demand? Any areas of care where you're seeing that most pronounced? And anything to note in terms of how broad based this is versus market specific? Marty BonickCEO at Ardent Health Partners00:19:15Yes. Craig, this is Marty. So just as building on what Alfred said, we've referenced before the strength of our market's growing on average, you know, about 3% a year, and so we see that as very durable. We know that there's some commentary between the payers and the providers, in terms of whether there's pent up demand. We don't subscribe to that theory. Marty BonickCEO at Ardent Health Partners00:19:35The strength of our markets, coupled with the strength of our performance, gives us strong conviction that we will continue to see strong volume growth. We accentuate that by the operational improvements we're making to be able to service that growth. But the strength of the markets that we're in gives us good conviction that these volumes are durable to from positive growth rate perspective. Craig HettenbachExecutive Director at Morgan Stanley00:20:00Got it. And then just as a follow-up on the COO hire, just any areas of strategic focus for him and and then also kind of experience he brings to your organization as you continue to look to scale the business? Marty BonickCEO at Ardent Health Partners00:20:12Yeah. Dave Dave's about one month on the job with us and is doing a great job, really just helping to, again, complement the existing executive team that we've put together. We've got great subject matter expertise across our hospitals, our health services, and our corporate services. Dave's background with both the consumer and retail focus will accentuate our consumer growth strategies as we go through the markets. And just to focus on and continued focus on integration and optimization of the entire platform, we've talked about the centralized centralized services that we've created in the years leading up to the IPO last summer. Marty BonickCEO at Ardent Health Partners00:20:49But we also said that we know that we've got 100 to 200 basis points of margin expansion to achieve over the next several years, and Dave will be a key focus in driving that performance improvement, coupled with the expected growth that we will see in new market or new hospital growth, complementing our existing markets. That integration activity will be paramount to making sure we can extract value from any transactions and making those accretive for the company. And so he'll have purview over, the execution of our ongoing initiatives as well as, that integration of new activity and growth into the system. Operator00:21:28Your next question is from the line of Ben Hendrix with RBC Capital Markets. Ben HendrixVice President at RBC Capital Markets00:21:35Great. Thank you very much. Just wanted to get an update on the expansion initiatives or the strategic initiatives you called out, specifically expanding your outpatient and acute footprint. Just any update on how conversations are going with potential new market opportunities and sellers in those markets? How are they thinking about valuation in the amid the uncertainty on the Medicaid policy changes and kind of just what you're seeing in terms of seller appetite? Ben HendrixVice President at RBC Capital Markets00:22:08Thanks. Marty BonickCEO at Ardent Health Partners00:22:09Ben, this is Marty again. Thanks for the question. We continue to focus on a multipart growth strategy. The first, we always said, was going to be inside of our markets. While we've got very strong inpatient market share, we know that there's still a lot of outpatient development work to be captured. Marty BonickCEO at Ardent Health Partners00:22:26Again, the acquisition we did with the NextCare Urgent Care assets in our Albuquerque and Tulsa markets, the 18 urgent care centers we bought, is a great indicator of that continued focus that we're going to have of strengthening the access points in our markets, strengthening our positions in those markets, and building out a more robust footprint, first and foremost. On the second part, in terms of new markets or new hospital growth, I would say the pipeline continues to build. Since going public, our visibility, you know, has, taken a new stage, and we've got more inbound calls, coming from, academic partners in particular, that have taken note of the model that we have and have a desire to grow inside of their respective regions but may not have, the balance sheet or the integrating operating experience, to expand into new regions and see Ardent as a a good target partner. So I'll say the conversations in the pipeline are growing, which is the reason that we're focusing on bringing in a dedicated chief development officer into the company, to be able to capitalize on those opportunities. In terms of valuations, you know, you've certainly seen some headline valuations that are above, historic norms and averages. Marty BonickCEO at Ardent Health Partners00:23:36I would characterize those as largely sort of one off strategic acquisitions for certain existing systems in a given geography. We believe that the overall valuations will continue to trade somewhere in the normal sense of where this industry has historically been. And any acquisition that we focus on is going to have to be something that we see as accretive to the company in the near term, call it, the first twenty four months, where we can see absent purchase price synergies that will help us to delever a transaction and make it accretive for shareholders. Ben HendrixVice President at RBC Capital Markets00:24:12Great. Thanks for the color. Operator00:24:17Your next question is from the line of Joanna Gajuk with Bank of America. Joanna GajukEquity Research Analyst at Bank of America00:24:24Hi, good morning. Thanks so much for taking the question. So I guess a follow-up on that comment around, I guess, to the prior question. So you mentioned that there's interest to it sounds like, receiving from the nonprofits and academic centers to partner. So can you give us a sense of those preliminary preliminary, you know, are these, you know, systems waiting essentially to see what's gonna happen or they're kinda ready to kinda, you know, do something right now? Joanna GajukEquity Research Analyst at Bank of America00:24:56So, essentially, what I was asking is sort of what, you know, a close of getting something done. Should we expect something this year or just this more kinda like next year when the dust sells? Any kind of indication, I guess, would be helpful. Marty BonickCEO at Ardent Health Partners00:25:09Yes. Marty BonickCEO at Ardent Health Partners00:25:10Joanne, this is Marty. I'll offer to chime in if there's additional. But we've been pretty open that we went public with the expectation of growth. We believe we've got a strong operating model that would be valuable to enter into new markets where we could create a partnership and, you know, create something more valuable for that target seller than that they were able to achieve on their own. We don't have anything definitive to announce today, obviously, and we will appropriately message that when there is. Marty BonickCEO at Ardent Health Partners00:25:39But I would say that there's a mix of conversations going on with potential near term opportunities as well as exploratory conversations about what future growth can look like in a in a given geography. You know, we are focusing on a mix of hospital acquisitions that would be both complementary to our existing markets or or state footprints we're in as well as new. And so, you know, we're just encouraged by that the the pipeline of growth and, again, the the reason why we're bringing on dedicated chief development officer to help nurture those relationships, conversations, and bring those to fruition. But we've been saying we've been hopeful that we will see some type of a transaction, whether that's a tuck in or a new market, know, still in this calendar year. Joanna GajukEquity Research Analyst at Bank of America00:26:25Okay. If I may, on the New Mexico DPP, like you said, you know, no approval yet, but there's some approvals coming out. So so any indication, like, would you assume to get this finalized by the end of q two? I mean, we're already in May. Thank you. Marty BonickCEO at Ardent Health Partners00:26:42Yeah. This is Marty again. On the DPP programs, we are starting to see a number of analysts noting that renewals of other states happening. We remain convicted that these programs are durable, You know, from our conversations at Washington, D. C. Marty BonickCEO at Ardent Health Partners00:26:58With elected officials, they know the importance of these programs to the states. Again, these DPPs were started under the first Trump administration, and I think the sense that we're seeing these new other state approvals come through are consistent with our conversations that we're having with the elected officials, both in the state and CMS, that it's just a matter of processing through these. And, you know, we are expecting approval. The the timing, we are hopeful for to see a q two approval, but, obviously, we can't control that. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:27:28And this is Alfred, Joanne. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:27:29The only thing I would add is that, you Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:27:31know, we stay close to our contacts in New Mexico, and I think we've been clear that all of the indications are that, you know, things are progressing as you would expect, and a very normal tracking towards an approval. Operator00:27:46Your next question is from the line of Matthew Gillmor with KeyBanc. Matthew GillmorDirector & Equity Research Analyst at KeyBanc Capital Markets00:27:53Hey, thanks. Wanted to ask about exchange volumes and payer mix. I think the presentation made reference to strength with exchange volumes. Can you provide some details in terms of the magnitude of the growth in the quarter and maybe update us in terms of the percent of revenue that's tied to exchanges versus, I think, the 3.6% you talked about for 'twenty four? Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:28:15Sure, Matt. This is Alfred. You know, like, all of our peers, we are seeing very strong exchange growth. For example, admissions in the quarter grew 40, in q one. That's a combination of, improvement in our additional enrollment in exchanges as well as new plans that we have that are ramping. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:28:38So our exchange volume growth, was significant. And, you know, today, q one, we're operating in the mid single digits as a percent of revenue. Matthew GillmorDirector & Equity Research Analyst at KeyBanc Capital Markets00:28:48Got it. That's helpful. And then following up on the comment around the moderation in professional expenses, I was hoping you could sort of unpack that a little in terms of the hospital based physician expense. You know, where are you seeing improvement? And, you know, are are you confident and comfortable that that'll be sort of a durable moderation? Matthew GillmorDirector & Equity Research Analyst at KeyBanc Capital Markets00:29:09Any any additional details there would be great. Thanks. Marty BonickCEO at Ardent Health Partners00:29:12Yeah, Matt. This is Marty. You know, we we have expected to see as we, you know, we could get guidance earlier in the year that, this was still gonna be an inflation that was north of, you know, sort of general inflation, and, you know, we've modeled that as such, and we are seeing that continue. And we are encouraged that it is moderating from the peak in 'twenty three. The rates came down a bit in 'twenty four. Marty BonickCEO at Ardent Health Partners00:29:35The growth, I should say, came down a bit in 'twenty four. We expect that to continue to moderate 'twenty five, but still be above normal inflation levels. So while Q1 was slightly ahead of where we thought things might be, we know, which is given some of the uncertainty of certain specialties, radiology is one that has been a bigger growth area as well as continued pressures in anesthesiology that we expect to see some continuation of this trend going throughout the remainder of the year as we had forecasted and guided earlier in the year. Operator00:30:16Your next question is from the line of Benjamin Rossi with JPMorgan. Benjamin RossiEquity Research Associate at JP Morgan00:30:24Great. Thanks for the question. So with 1Q revenue per adjusted admission at about 1.2% on respiratory tract acuity and more challenging year over year comp. Benjamin RossiEquity Research Associate at JP Morgan00:30:36To start there, is there anything else Benjamin RossiEquity Research Associate at JP Morgan00:30:38from a payer mix or acuity perspective that we aren't seeing within there such as additional drag from your efforts or rationalizing your outpatient surgery offerings? And then in reaffirming your guide, what puts and takes are you factoring into reaching the lower end or upper end of your 2025 pricing guidance of 2.1% to 4.4% year over year? Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:30:59Ben, it's Alfred. I'll start with the first part of your question on the NPR per AA growth of 1.2%. You touched on a piece of it, the service mix and acuity. Clearly, that was on a year over year basis a drag. We continue to see good the year over year commercial rate increases have been very consistent with our expectations. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:31:24The other items that were dragged on a year over year basis, we talked about the denials, you know, which we will lap in the middle of the year. So you'll get a more normalized, you know, growth rate on a year over year basis. And then the last thing is is that transfer, and Marty touched on it in his comments, the transfer of the oncology services. You know, that was about 70 basis points, as well. So, really, those three items, were the were the drag on a year over year basis. Benjamin RossiEquity Research Associate at JP Morgan00:31:55Great. And then as a follow-up on the transfer center operations, you mentioned the improvements to your transfer center more broadly on a regional basis. Could you just walk us through those efforts and your approach more broadly to inpatient capacity and related patient throughput during this elevated patient utilization backdrop? Marty BonickCEO at Ardent Health Partners00:32:15Yes, Evan, this is Marty. So we have regionalized our transfer center operations. And, as you all know, we have one instance of EPIC as our electronic health record and really our clinical operating system that helps us drive and have visibility in terms of where we have capacity opportunities. Know, taking that technology and the organization of those services has allowed us to have a very, you know, seamless process for outlying rural regional hospitals to be able to transfer patients into our networks and help us to drive that volume to the most appropriate setting. So not only are we trying to maximize volumes coming into our tertiary hospitals, but our secondary hospitals, which may not have gotten the original call, we're able to relocate those patients, where we've got the appropriate clinical mix of physicians and services to to service those patients and manage capacity and demand across the a broader network. Marty BonickCEO at Ardent Health Partners00:33:07And so before that that was all happening, you know, on a one off basis, and if you called hospital x and they had availability, they'd accept it. Now you're calling the market, and the market is helping to distribute those patients more effectively across our footprint, which is helping us to see increased pull through in those transfers, getting placed in in one of our hospital beds. Alfred LumsdaineChief Financial Officer at Ardent Health Partners00:33:28And, Ben, this is Alfred. I wanna go back to the first part of your question because you asked about the, you know, kinda what are the range of outcome in terms of the items would it that would affect the range from the top end to the bottom end of our guidance. You know, obviously, we're very pleased with the start of the year and the solid Q1 that we had. I would just point you back to the things we've talked about, the pressure of professional fees, the payer behaviors and denials is their variance to those expectations. And then, of course, tariffs, we've touched on relatively minor in terms of the overall exposure, but certainly not something that we had anticipated in our guide. Operator00:34:09At this time, there are no further questions. I will now hand the call back over to management for closing remarks. Marty BonickCEO at Ardent Health Partners00:34:16Thank you, everybody, for your time and attention. We appreciate the support of Ardent and our performance. If there's any follow-up questions, please refer those to Dave Styblo, Head of Investor Relations for Ardent. Thank you, everybody. Operator00:34:29This concludes today's call. Thank you for joining. You may now disconnect your lines.Read moreParticipantsExecutivesDavid StybloSVP - Investor RelationsMarty BonickCEOAlfred LumsdaineChief Financial OfficerAnalystsWhit MayoSenior Managing Director at Leerink PartnersAnn HynesSenior Healthcare Services Equity Analyst & Managing Director at Mizuho Financial GroupCraig HettenbachExecutive Director at Morgan StanleyBen HendrixVice President at RBC Capital MarketsJoanna GajukEquity Research Analyst at Bank of AmericaMatthew GillmorDirector & Equity Research Analyst at KeyBanc Capital MarketsBenjamin RossiEquity Research Associate at JP MorganPowered by